Processa Pharmaceuticals Inc. (NASDAQ: PCSA) is “One to Watch”
Oct 6, 2020
- Processa Pharmaceuticals aims to develop products where existing clinical evidence of efficacy already exists in the targeted unmet medical need condition with the drug itself or a drug with very similar pharmacology
- The Processa process focuses on the advancement of drugs that are ready for clinical development or have minimal pre-IND enabling studies to complete
- Processa’s current development pipeline features multiple clinical drug candidates, given the recent acquisitions of three additional development-focused licensing agreement since June 2020
- In total, the company’s combined scientific, development and regulatory experience has resulted in more than 30 drug approvals by the U.S. Food and Drug Administration
Processa Pharmaceuticals (NASDAQ: PCSA) aims to develop products where existing clinical evidence of efficacy already exists in unmet medical need conditions. In support of this goal, the company has assembled an unparalleled management team, board of directors and product development team featuring experts in developing drug products, from IND-enabling studies to NDA submission. In total, the team’s combined scientific, development and regulatory experience has resulted in more than 30 drug approvals by the U.S. Food and Drug Administration (“FDA”) and more than 100 meetings with the FDA while working on more than 50 drug development programs, including drug products targeted to orphan disease and unmet medical need conditions.
Headquartered in Hanover, Maryland, Processa has built a pipeline of drugs which already have some proof-of-concept clinical data supporting clinical use in…
NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.
More News
Melanoma Vaccine Ushers in New Hope for Cancer Patients
Beyond melanoma, scientists are studying cancer vaccines for glioblastoma, pancreatic cancer and more.
Why Anger About Data Centers and Energy Prices May Not Swing Votes
In Ohio, many voters say their frustration about the increase in electricity and fuel prices and the growth of data centers won’t influence whom they vote for.
U.S. Government Takes a Cut of Chip Business in Japan-Funded Deal
President Trump’s novel deal-making is on display in upstate New York, where the administration is funneling Japanese funds into a government-owned chip factory.
A Fight Over Felon Voting Prompts a Free Speech Debate
A Minnesota group worried that its opposition could expose it to prosecution under the state’s deceptive-practices law. Its lawsuit could have wide implications for limiting speech around elections.
The little-known investment Martin Lewis wants you to understand...
The little-known investment Martin Lewis wants you to understand
Heading to France? Amid Recent Unrest, Here’s What to Know
Demonstrations are expected to continue this weekend in Paris and other French cities. Some museums and tourist sites will be closed, and visitors should expect a strong police presence.
Civil servant who juggled five jobs says he was 'surprised' to be charged with fraud
Kashim Chowdhury denied being dishonest when not telling employers he had other jobs.
Republicans Cut Taxes to Win the Midterms. It May Not Work Out.
Among the stakes in next month’s election is the long-running question of whether tax cuts can shape how people vote.
A.I. and New Rules for Accounting Are an Opportunity for Start-Ups
Pennylane, a French company, has gained market share in its home country by helping accountants work with clients. It’s aiming to expand internationally.
Volvo Shares Plunge as China Ambitions Fade for Western Carmakers
The Swedish automaker plans to cut another 2,500 jobs, joining competitors in offering a gloomy view of the world’s biggest car market.
What is PHP and why did it spark a global cyber-security scramble?
AI uncovered long-hidden programming flaws, triggering a rare global cyber-security response.
Island inflation rate rises to 3%, figures show
The rising cost of food and alcohol drives an increase in the inflation rate, figures show.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.